Moreover, mTOR inhibition (everolimus) increases Bcl-2/Mcl-1 ratio in HMCLs by enhancing the binding of transcription factors IKZF3 and Blimp-1 to the BCL2 promoter and therefore enhances venetoclax anti-MM effects (120). Here, MCL1 is linked to Miyoshi myopathy.